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Background: Diabetes is an important reason for end-stage renal failure and diabetic foot wounds worsen the life
qualities of these patients. Protein and amino acid support accelerates the wound healing. The purpose of this
retrospective study is to examine the effect of beta-hydroxy-beta-methylbutyrate, arginine and glutamine
(AboundW) supplementation on the wound healing.
Methods: A total of 11 diabetic dialysis patients were included in this retrospective study aiming to evaluate the
effect of the diet support with beta-hydroxy-beta-methylbutyrate, arginine and glutamine on wound healing in
diabetic dialysis patients. Pre-treatment and post-treatment wound depth and wound appearance were scored in
accordance with the “Bates-Jensen” wound assessment tool. The results of 4-week treatment with beta-hydroxy-
beta-methylbutyrate, arginine and glutamine (AboundW) support were evaluated in terms of wound healing.
Results: The mean age of patients was 66 (SD: 10, range: 51-81) and 9 (81.8%) of them were males. After the
4-week treatment, in accordance with the Bates-Jensen scoring, healing was observed on the wound depth score
of 7(63.6%) patients and on wound appearance score of 8(72.7%) patients out of 11. While the wound depth score
of 4(36.4%) cases and wound appearance score of 3(27.3%) cases remained the same, no deterioration was
observed on any cases throughout the follow-up period.
Conclusion: In conclusion, our findings revealed that Abound treatment makes a positive contribution to the
wound healing in diabetic dialysis patients.
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Today, diabetes and chronic glomerulonephritis are still
among the most frequent reasons of the end-stage renal
failure. More than 20% of patients receiving the dialysis
treatment are diabetic [1]. Microvascular and neuro-
logical complications including retinopathy-related vis-
ual impairment and peripheral neuropathy that develop* Correspondence: savassipahi@yahoo.com
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reproduction in any medium, provided the oramong the diabetic patients adversely affect the quality
of life, especially in the dialysis patients.
Foot ulcer is one of the most frequently encountered
complications in diabetic dialysis patients with periph-
eral neuropathy and ischemia. Diabetic foot ulcers are
known to become frequently infected which leads an in-
crease in the risk of amputation unless treated at earlier
stages [2]. Both the circulation failure and impaired im-
mune response in diabetic dialysis patients have negative
effects on the wound healing. Characterized by a dy-
namic and complex process that involves phases of in-
flammation, proliferation, and remodeling that lead totd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 “Bates-Jensen” wound assessment tool
Wound depth score Wound appearance score
Necrotic 1 Necrotic 1
Deep 2 Scabbed 2
Moderate 3 Granulated 3
Easy 4 Epithelial 4
Minimal 5 Closed 5
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[3], wound healing depends on adequate nutrient flow
with substantial role of early aggressive nutrient and
micro-nutritional feeding in the control and prevention
of this process [4]. In this regard, essential amino acids
play a significant role in wound healing in relation to
their role in the production of inflammation and fibro-
blast products. Arginine is one of the most important
amino acids that accelerate the wound healing [5] while
glutamine is defined as “situational essential amino acid”
which is used by fibroblasts as the primary energy re-
source for proliferation [6]. Hydroxy methylbutyrate
(HMB) is the leucine metabolite, which is an essential
amino acid [7] shown to have positive effects on the
wound healing [8]. Although beta-hydroxy-beta-methyl-
butyrate, arginine and glutamine (AboundW) support is
known to accelerate the wound healing process [9], there
is limited information regarding the case in diabetic dia-
lysis patients.
The purpose of this retrospective study is to evaluate
the effect of the diet support with beta-hydroxy-beta-
methylbutyrate, arginine and glutamine on wound heal-
ing in diabetic dialysis patients.
Methods
Study population
A total of 11 diabetic dialysis patients were included in
this retrospective study aiming to evaluate the effect of
the diet support with beta-hydroxy-beta-methylbutyrate,
arginine and glutamine on wound healing in diabetic
dialysis patients. Cases treated with haemodialysis due to
chronic renal failure (CRF) and receiving oral supple-
mentation with AboundW due to diabetic foot wound
were included in the present study, while patients who
were treated with antibiotics for long periods, received
steroid treatment or hyperbaric oxygen therapy were
excluded.
As a part of routine practice in the study centre, writ-
ten informed consent was obtained from all patients
considering use of their photos for any possible scientific
publication in the future. The study which was con-
ducted in accordance with the ethical principles stated
in the “Declaration of Helsinki”. Additionally, while the
present study was exempt from the requirement of eth-
ical approval in relation to its retrospective design, the
permission was obtained from our institutional ethics
committee (Clinical Research Ethics Committee of
Sakarya University) for the use of patient data for publi-
cation purposes.
Assessments
Data were extracted from the institutional database
“Nefromed Dialysis Center” database (Sakarya, Turkey)
including laboratory analyses performed by “SystemMedical Labs” (Istanbul / Turkey). Data on demograph-
ics and basic clinical and laboratory data of selected
patients who commenced their treatment between May-
August 2011were recorded before the treatment. The
pre-treatment and post-treatment wound depth and
wound appearance of patients were scored in accordance
with “Bates-Jensen” wound assessment tool shown in
Table 1 [10]. Photos of all of the lesions were taken both
before and after the treatment. The results of 4-week
treatment with beta-hydroxy-beta-methylbutyrate, argin-
ine and glutamine (AboundW) supplementation were
evaluated in terms of wound healing. Pre and post treat-
ment values were compared with either paired t test or
Wilcoxon test regarding distribution pattern.
Treatment
The patients received the oral supplementation with a
combination of beta-hydroxy-beta-methylbutyrate, ar-
ginine and glutamine (AboundW) twice the same mixture
per day for 4 weeks as follows; the bags containing 1.3 g
HMB, 7.4 g arginine, and 7.4 g glutamine with water of
120 cc day and night.
Results
Demographics, basic clinical and laboratory
characteristics
Patient demographics revealed that the mean age of
patients included in the study (n=11) was 66 years (SD:
10, range: 51-81) while males composed 81.8% (n=9) of
the study population (Table 2).
The mean (SD) hemodialysis (HD) period of patients
was 65(8) months. A total of 10 patients for the brachial
arterio-venous fistula and 1 patient for the permanent
jugular haemodialysis catheter took the low-flux haemo-
dialysis treatment. Nine patients had been on long+short
acting insulin treatment.
According to basic clinical and laboratory data of
patients as illustrated in Table 2, there was no significant
influence of treatment on clinical and laboratory findings
except for increase in alanine aminotransferase (ALT, U/L;
12.4(2.0) vs. 14.9(2.6), p=0.04) and decrease in sodium
(Na, mmol/L, 142.0(2.0) vs. 139.0(2.0), p=0.01) levels.
Accordingly, the mean level for HbA1c was 6.6 (SD: 0.4,
range: 6-8.2) and 6.5(SD: 1.4, range: 5.4-9.5) before
and after the treatment, respectively. The mean (SD)
Table 2 Patient demographics and basic clinical and laboratory findings
Mean(SD) Range
Age (years) 66 (10) 51-81
Gender (male,%) 81
Clinical/laboratory findings Pre-treatment Post-treatment p value
Mean(SD)
SBP (mmHg) 128(12) 130.0(9.0) 0.60
DBP (mmHg) 86 (10) 88.0(10.0) 0.62
HbA1c (%) 6.6(0.9) 6.5(1.4) 0.85
CRP (mg/dl) 8.9(5.8) 9.7(7.8) 0.81
Albumin (gr/dl) 4.0(0.3) 4.1(0.0) 0.89
Hemoglobin (gr/dl) 11.7(2.0) 11.5(2.0) 0.79
WBC (103/μL) 6.9(1.7) 6.2(1.3) 0.3
Urea (mg/dl) 159.0(49.0) 146.0(47.0) 0.56
Creatinine (mg/dl) 6.6(1.7) 6.5(2.1) 0.89
Total cholesterol (mg/dl) 159.0(37.0) 166.0(53.0) 0.75
Triglyceride (mg/dl) 192.0(162.0) 249.0(214.0) 0.54
ALT (U/L) 12.4(2.0) 14.9(2.6) 0.04
Na (mmol/L) 142.0(2.0) 139.0(2.0) 0.01
K (mmol/L) 5.5(0.3) 5.2(0.8) 0.33
SBP: systolic blood pressure; SD: standard deviation; DBP: diastolic blood pressure; CRP: C-reactive protein (CRP); ALT: alanine aminotransferase; Na: sodium; K:
potassium.
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mg/dl and 9.7(7.8) mg/dl before and after the treatment,
respectively (p=0.81).
Treatment outcome
After the 4-week treatment, in accordance with the
Betas-Jensen scoring, healing was observed on the
wound depth score of 7(63.6%) patients and on wound
appearance score of 8(72.7%) patients out of 11. While
the wound depth score of 4(36.4%) cases and wound ap-
pearance score of 3(27.3%) cases remained the same, noTable 3 Pre-treatment and post-treatment wound appearance
Wound appearance score
Pre-treatment Post-treatm
Patient 1 1 5
Patient 2 5 5
Patient 3 3 4
Patient 4 1 3
Patient 5 2 4
Patient 6 4 5
Patient 7 2 5
Patient 8 2 4
Patient 9 3 5
Patient 10 2 2
Patient 11 3 3deterioration was observed on any cases throughout the
follow-up period (Table 3, Figure 1). Wound appearance
(p=0.001) and depth (p=0.006) scores improved signifi-
cantly with treatment (Table 4). The drug was tolerated
well by the patients and no side effect was observed
regarding the drug.
Discussion
Diabetes is one of the most frequent reasons of end-
stage renal failure and a well-established cause of the de-














Figure 1 Pre-treatment and post-treatment wound appearances of the selected patients.




Wound appearance score 2.0(1.0) 4.0(2.0) 0.011
Wound depth score 3.0(2.0) 5.0(2.0) 0.006
IQR: inter-quartile range.
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as a complication during their lifetime [11]. Further-
more, independent of diabetes, renal failure has been
reported to markedly increase the risk of diabetic foot
ulceration and amputation [3,12]. Hence the coexistence
of these two conditions, there is a double threat for de-
velopment of foot lesions which impair the patient’s
quality of life, increase health care costs, and, for
patients who require surgical interventions, there is a
higher mortality compared with patients without renal
disease [3].
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metabolic and catabolic state, wound healing is a complex
chain of biochemical events during which nutritional
needs are significantly increased [4]. It is a well-known
fact that protein and amino acid support accelerates the
wound healing. In this retrospective study, it was deter-
mined that the nutrition support combination consisting
of beta-hydroxy-beta-methylbutyrate, arginine and glu-
tamine would be useful for the treatment of foot ulcers,
which are encountered as an important problem in dia-
betic dialysis patients.
Due to its rapid metabolism, the wound needs high
amounts of nutritional elements while protein-calorie
malnutrition extends the phase of inflammation with
negative effects on the fibroplasia, proteoglycans and
collagen synthesis. Essential amino acids play a signifi-
cant role in wound healing by increasing the production
of inflammation and fibroblast products [13]. Beta-
hydroxy-beta-methylbutyrate is a leucine metabolite. It
decreases the proteolysis, increases the protein synthesis,
decreases the apoptosis and increases the cell prolifera-
tion. HMB is generally used safely as support in patients
with malnutrition, cancer, chronic disease, sepsis and
HIV [14]. Being a product of the ornithine metabolism,
arginine is required for the cell proliferation, regener-
ation and collagen synthesis [5]. Glutamine is not essen-
tial for the body; however, it is the most intense amino
acid in the body that regulates the cell functions, coordi-
nates the immune parameters, displays an anti-oxidant
effect and regulates the adjuvant T-cell functions [6]. In
a study by Arana et al. evaluation of the effect of argin-
ine treatment on healing of foot ulcer in 11 diabetic
patients revealed that the recovery was complete for 8
patients and considerable for 3 patients [15]. Costa et al.
indicated that glutamine support significantly improved
the laceration strength of wound and increased the per-
centage of mature collagen area [16]. Likewise, HMB is
known to have positive effects on wound healing.
Abound is a special formula that is consisted of beta-
hydroxy-beta-methylbutyrate, arginine and glutamine
that supports the wound healing and enables the struc-
turing of lean body mass. This combination is potentially
used among patients with cancer, sarcopenia, trauma,
chronic diseases, chronic obstructive lung disease and
HIV [17,18]. However, the studies previously conducted
have concluded that this product also accelerates the
wound healing. In their study that was performed on 18
healthy adults older than 70 years of age, Williams et al.
indicated that the Abound support increased the colla-
gen synthesis and accelerated the wound healing [19].
The period of ulcer healing was also shown to be signifi-
cantly shortened with by Tatti et al. in retrospective
evaluation of 12 patients with diabetic foot who were re-
ceiving the Abound treatment [20]. Likewise, ourfindings also indicated that the healing was observed on
wound depth score of 7 patients and on wound appear-
ance score of 8 patients out of 11. While the wound
depth score of 4 cases and wound appearance score of 3
cases remained the same, no deterioration was observed
on any cases throughout the follow-up. In line with no
negative side effect associated with the Abound treat-
ment in the literature, none of our patients experienced
a negative effect throughout the treatment.
The major limitation of the present study is its retro-
spective design as an uncontrolled series of diabetic
haemodialysis patients besides the small sample size.
Nevertheless, given that malnutrition is a common and
well-known deleterious outcome in dialysis patients
which delays wound healing, our findings indicating that
beta-hydroxy-beta methylbutyrate, arginine and glutam-
ine may be very beneficial in these patients by not only
improving wound healing seem notable.
Conclusion
In conclusion, our findings indicate the benefit of beta-
hydroxy-beta-methylbutyrate, arginine and glutamine
support in wound healing including diabetic foot among
diabetic dialysis patients. Nevertheless, given the small
sample size as well as retrospective design of the present
study, future larger-scale prospective studies would be
warranted to conclude the efficacy of beta-hydroxy-beta-
methylbutyrate, arginine and glutamine supplementation
in wound healing among diabetic dialysis patients.
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